Antisense compounds, compositions and methods are provided for modulating the expression of SRC-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding SRC-1. Methods of using these compounds for modulation of SRC-1 expression and for treatment of diseases associated with expression of SRC-1 are provided.
Claims What is claimed is: 1. An antisense compound 8 to 30 nucleobases in length targeted to nucleotides 14 through 31 of a 5' untranslated region, nucleotides 27 through 46 of a start codon, nucleotides 63 through 80, nucleotides 120 through 137, nucleotides 203 through 220, nucleotides 283 through 300, nucleotides 339 through 356, nucleotides 482 through 499, nucleotides 822 through 839, nucleotides 907 through 924, nucleotides 1200 through 1217, nucleotides 1301 through 1318, nucleotides 1710 through 1727, nucleotides 1886 through 1903, nucleotides 2047 through 2064, nucleotides 2370 through 2387, nucleotides 2757 through 2774, nucleotides 2963 through 2980, nucleotides 3288 through 3305, nucleotides 3491 through 3508, nucleotides 3697 through 3714, nucleotides 4072 through 4089, nucleotides 4243 through 4260 of a coding region, nucleotides 4353 through 4383 of a stop codon, or nucleotides 4466 through 4483 of a 3' untranslated region of SEQ ID NO. 3 encoding human SRC-1, wherein said antisense compound specifically hybridizes with and inhibits the expression of human SRC-1 gene. 2. The antisense compound of claim 1 which is an antisense oligonucleotide. 3. An antisense compound up to 30 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO: 10, 12, 13, 14, 15, 16, 17, 19, 20, 22, 23, 24, 26, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 44, 48, 18, 25, 27, 46, 47 or 49 which inhibits the expression of human SRC-1. 4. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 5. The antisense compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage. 6. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 7. The antisense compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 8. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 9. The antisense compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine. 10. The antisense compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 11. A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent. 12. The pharmaceutical composition of claim 11 further comprising a colloidal dispersion system. 13. The pharmaceutical composition of claim 11 wherein the antisense compound is an antisense oligonucleotide. 14. A method of inhibiting the expression of human SRC-1 in cells or tissues comprising contacting said cells or tissues in vitro with the antisense compound of claim 1 so that expression of human SRC-1 is inhibited. 15. The antisense compound of claim 3 which is an antisense oligonucleotide. 16. The antisense compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 17. The antisense compound of claim 16 wherein the modified internucleoside linkage is a phosphorothioate linkage. 18. The antisense compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 19. The antisense compound of claim 18 wherein the modified sugar moiety is a 2'-methoxyethyl sugar moiety. 20. The antisense compound of claim 15 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 21. The antisense compound of claim 20 wherein the modified nucleobase is a 5-methylcytosine. 22. The antisense compound of claim 15 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 23. A method of inhibiting the expression of human SRC-1 in human cells or tissues comprising contacting said cells or tissues in vitro with the antisense compound of claim 3 so that expression of human SRC-1 is inhibited. 24. A composition comprising the antisense compound of claim 3 and a pharmaceutically acceptable carrier or diluent. 25. The composition of claim 24 further comprising a colloidal dispersion system. 26. The composition of claim 24 wherein the antisense compound is an antisense oligonucleotide. 